- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT07840976
Immunotargeted Therapy Plus Low-Dose Chemotherapy in Newly Diagnosed Adult Ph+ B-ALL (Ph+ ALL-2026)
A Prospective, Umbrella, Phase 2 Study of Immunotargeted Agents Combined With Low-Dose Chemotherapy in Adult Patients With Newly Diagnosed Philadelphia Chromosome-Positive B-Cell Acute Lymphoblastic Leukemia
This is a prospective, open-label, single-arm, umbrella phase 2 clinical trial enrolling 22 adult patients with newly diagnosed Philadelphia chromosome-positive (Ph+) B-cell acute lymphoblastic leukemia (ALL).
As an umbrella trial, all patients share the same target disease (newly diagnosed Ph+ B-ALL) and receive a uniform induction backbone consisting of multi-targeted immunotherapy, targeted therapy, and reduced-intensity chemotherapy. After induction, patients are stratified and assigned to two distinct consolidation pathways based on clinical condition, performance status, resource availability, and patient preference:
Pathway A: Consolidation with CD19-directed CAR-T cell therapy to achieve deep molecular remission; Pathway B: Consolidation with sequential immunochemotherapy to maximize minimal residual disease (MRD) clearance.
A backup chemotherapy backbone is provided for patients ineligible for antibody therapy. All patients, regardless of consolidation pathway, proceed to a unified long-term maintenance regimen. The primary endpoint is the complete molecular remission (CMR) rate after one cycle of induction therapy. MRD is monitored longitudinally by flow cytometry, quantitative PCR, and immune repertoire sequencing. Safety is evaluated per NCI CTCAE version 5.0.
Study Overview
Status
Conditions
Study Type
Enrollment (Estimated)
Phase
- Phase 2
Contacts and Locations
Study Contact
- Name: Ying Wang, MD, PhD
- Phone Number: +86 22-23608095
- Email: wangying1@ihcams.ac.cn
Study Locations
-
-
Tianjin Municipality
-
Tianjin, Tianjin Municipality, China, 301600
- Chinese Academy of Medical Sciences Hospital of Hematology (Chinese Academy of Medical Sciences Institute of Hematology)
-
Contact:
- Runxia Gu
- Phone Number: +86-22-23608095
- Email: gurunxia@ihcams.ac.cn
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Age ≥ 18 years
- Newly diagnosed, previously untreated Philadelphia chromosome-positive B-cell acute lymphoblastic leukemia (Ph+ B-ALL) confirmed by cytogenetics and/or molecular testing
- Leukemic blasts expressing CD22
- Adequate organ function (renal, hepatic, cardiac)
- Eastern Cooperative Oncology Group (ECOG) performance status 0-2
- Life expectancy ≥ 3 months
- Written informed consent obtained prior to any study-related procedures
Exclusion Criteria:
- Prior systemic anti-leukemic therapy, including chemotherapy, targeted therapy, or immunotherapy
- History of chronic myeloid leukemia (CML) or other hematologic malignancies
- Central nervous system (CNS) leukemia or extramedullary disease at diagnosis
- Uncontrolled active infection or severe comorbidities
- HIV positivity or known hepatitis B/C infection with active viral replication
- Pregnant or breastfeeding
- Inability to comply with study procedures or follow-up requirements
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Sequential Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Experimental: Immunotargeted Therapy + Low-Dose Chemotherapy Arm
All patients receive a uniform induction therapy backbone combining targeted therapy, immunotherapy, and reduced-intensity chemotherapy. After induction, patients are stratified into two consolidation pathways based on clinical status: 1) CD19 CAR-T cell therapy; 2) sequential immunochemotherapy. All patients proceed to a unified long-term maintenance regimen. |
Third-generation tyrosine kinase inhibitor (TKI) targeting BCR::ABL1, administered orally daily as part of induction, consolidation, and maintenance therapy. BCL-2 inhibitor administered orally daily during induction and consolidation cycles to enhance leukemic cell apoptosis. Anti-CD22 antibody-drug conjugate (ADC) administered intravenously during induction and consolidation therapy. CD19/CD3 bispecific T-cell engager (BiTE) administered as continuous intravenous infusion during consolidation therapy. Autologous CD19 CAR-T cell therapy administered as a single intravenous infusion as optional consolidation therapy for eligible patients. |
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Complete Molecular Remission (CMR) Rate After 1 Cycle of Induction Therapy
Time Frame: At the end of Cycle 1 (each cycle is 28 days, approximately 4 weeks from enrollment)
|
The proportion of patients achieving complete molecular remission (CMR), defined as undetectable BCR::ABL1 transcript by quantitative PCR (BCR::ABL1/ABL1 ratio < 0.001%), after 1 cycle of induction therapy. |
At the end of Cycle 1 (each cycle is 28 days, approximately 4 weeks from enrollment)
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
3-Month Complete Remission (CR)
Time Frame: 3 months after study enrollment
|
3 months after study enrollment
|
|
|
3-Month MRD Negativity Rates
Time Frame: 3 months after study enrollment
|
3 months after study enrollment
|
|
|
2-Year Overall Survival (OS)
Time Frame: 2 years after the last patient enrollment
|
OS is defined as the time from study enrollment to death from any cause. |
2 years after the last patient enrollment
|
|
2-Year Disease-Free Survival (DFS)
Time Frame: 2 years after the last patient enrollment
|
DFS is defined as the time from study enrollment to disease relapse or death from any cause. |
2 years after the last patient enrollment
|
|
2-Year Event-Free Survival (EFS)
Time Frame: 2 years after the last patient enrollment
|
EFS is defined as the time from study enrollment to first occurrence of predefined adverse events, disease progression or death. |
2 years after the last patient enrollment
|
|
Incidence of Treatment-Related Adverse Events (TRAEs)
Time Frame: From study enrollment to 60 days after the last treatment
|
Number and severity of adverse events graded according to NCI CTCAE version 5.0. |
From study enrollment to 60 days after the last treatment
|
Collaborators and Investigators
Study record dates
Study Major Dates
Study Start (Estimated)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Amino Acids, Peptides, and Proteins
- Proteins
- Carbohydrates
- Glycosides
- Antibodies, Monoclonal, Humanized
- Antibodies, Monoclonal
- Antibodies
- Immunoglobulins
- Immunoproteins
- Blood Proteins
- Serum Globulins
- Globulins
- Aminoglycosides
- Calicheamicins
- Inotuzumab Ozogamicin
- venetoclax
- blinatumomab
- olverembatinib
Other Study ID Numbers
- IIT2026061
- IIT2026061-EC-1 (Other Identifier: Ethics Committee of Institute of Hematology & Blood Diseases Hospital, CAMS & PUMC)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.